Navigation Links
Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
Date:5/13/2013

NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the U.S. Patent and Trademark Office (USPTO) has allowed a key patent application in the Company's portfolio.  The patent application "Alpha Emitting Constructs and Uses Thereof" is licensed by Actinium Pharmaceuticals from Memorial Sloan Kettering Cancer Center (MSKCC). 

The application covers treatment of metastatic solid cancers by targeting either cancer cells directly or blood vessels that provide for their growth with appropriate carriers of alpha emitting isotopes actinium 225 and bismuth 213.  This technology allows Actinium Pharmaceuticals to expand use of its platform beyond blood borne and bone marrow located cancers, thus potentially offering broad categories of severely ill patients an efficacious therapy with a safety profile that could allow treatment of such patients.  The patent is expected to issue in the next few months. Actinium Pharmaceuticals retains an exclusive license to use, develop, and commercialize this patent.

Dragan Cicic , MD, CMO of Actinium Pharmaceuticals, said: "This decision is an important step towards our goal of expanding the use of our technology to address the vast unmet medical need area of metastatic cancers in older patients.  We have the potential to not only improve efficacy of cancer treatment but also enable it in many patients too sick to withstand the rigors of currently available therapies."

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or Contact:

Segio Traversa , CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr. , 203-258-0159
Email: dsdobson@optonline.com 
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
2. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
3. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
4. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
5. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
6. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
7. Actinium Pharmaceuticals Announces New Round of Financing
8. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
9. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
10. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
11. Actinium Pharmaceuticals Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:7/1/2017)... 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be accessed ... It will be archived for replay following the conference call. ...
(Date:6/30/2017)... Medical (AVACEN) announced the publication of new research in the peer-reviewed ... AVACEN Treatment Method to significantly reduce the widespread pain ... ... ... 200 to 400 million people worldwide according to The National Fibromyalgia ...
Breaking Medicine Technology:
(Date:7/20/2017)... Visalia, CA (PRWEB) , ... July 20, 2017 , ... ... has announced the addition of Horine Chiropractic , directed by Dr. Russell Horine, ... as it is completely family run with Dr. Russell Horine serving as the clinic ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today ... received his BS in Biology from LSU, graduating summa cum laude. He attended Emory ... After his residency in St. Louis, Dr. Dunbar moved to New York to complete ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... services since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, ... all major international travel insurance products online, under their own brand. The online ...
(Date:7/20/2017)... ... ... Dr. Jig Patel is pleased to announce openings for new patients who are ... difficulties that face people who are missing teeth , he offers education about ... and bridges. Not only does an implant improve oral health, it also restores the ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... hiring senior healthcare project manager, Josh Christensen. As a leader in healthcare construction, ... to further its healthcare resume in the Midwest with Josh now on board. ...
Breaking Medicine News(10 mins):